We spoke to Dr Luigi Di Biase (Albert Einstein College of Medicine, Montefiore Medical Center, New York, NY, USA) on the current and new, emerging treatment strategies for the treatment of persistent atrial fibrillation, including the limitations of current pulmonary vein isolation, the concept of “beyond PVI” and clinical evidence supporting new ablation targets.
Questions:
- What are the limitations of current pulmonary vein isolation (PVI) strategies in the treatment of persistent atrial fibrillation (AF)? (0:18)
- Could you give us an overview of the new and emerging ablation targets in persistent AF? (3:07)
- What do you feel complicates the concept of “beyond PVI”? (4:55)
- What clinical evidence supports approaches involving new ablation targets? (6:46)
Speaker disclosures: Dr Di Biase is a consultant for Biosense Webster, Stereoataxis and Rhythm management and has received speaker honoraria/travel support from Biosense Webster, St. Jude Medical (now Abbott), Boston Scientific, Medtronic, Biotronik, Pfizer and Bristol Meyers Squibb.
Commissioned, edited and funded by Touch Medical Media.
Filmed during a remote video call with Dr Luigi Biase as a highlight of the AF Symposium, January 2021.
